Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 5/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.59 |
| ▸ | STIM1 | Q13586 | 7/20 | 0.57 |
| ▸ | ORAI1 | Q96D31 | 7/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195868 | 0.79 | STIM1 (0.83) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL22643388 | 0.78 | KEAP1 (0.64) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL181689 | 0.75 | STIM1 (0.85) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL26628275 | 0.74 | STIM1 (0.86) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL29946185 | 0.74 | STIM1 (0.86) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL23557721 | 0.73 | HSD17B1 (0.72) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL26628325 | 0.72 | STIM1 (1.00) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL29946160 | 0.72 | STIM1 (1.00) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL14226913 | 0.72 | STIM1 (0.63) | KEAP1NFE2L2STIM1ORAI1CA12 | |
| SCHEMBL22833938 | 0.72 | CYP1B1 (0.63) | KEAP1NFE2L2STIM1ORAI1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895688-B2 | Halogen-free flame retarding materials based on bisphenol triazole resins and polymers | UNIVERSITY OF MASSCHUSETTS (US) | 2014-11-25 | — | — | US | disclosed |
| US-20120316313-A1 | HALOGEN-FREE FLAME RETARDING MATERIALS BASED ON BISPHENOL TRIAZOLE RESINS AND POLYMERS | UNIVERSITY OF MASSACHUSETTS | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316313-A1 | HALOGEN-FREE FLAME RETARDING MATERIALS BASED ON BISPHENOL TRIAZOLE RESINS AND POLYMERS | FFAR3, FHIT, BRPF3 | KEAP1 1265/4885NFE2L2 2377/4885STIM1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.